BMY - NYSE - 3/12/2010 8:00 PM
| Current | Overall Rank | Sector Rank | Industry Rank |
|---|---|---|---|
| $8.51B | 88 / 4096 | 11 / 503 | 8 / 19 |
| Healthcare | Drug Manufacturers - Major |
| Period | Cash on Hand |
|---|---|
| Sep/99 | $2.69B |
| Dec/99 | $2.96B |
| Mar/00 | $2.68B |
| Jun/00 | $2.42B |
| Sep/00 | $2.96B |
| Dec/00 | $3.38B |
| Mar/01 | $2.94B |
| Jun/01 | $3.15B |
| Sep/01 | $3.08B |
| Dec/01 | $5.65B |
| Mar/02 | $3.58B |
| Jun/02 | $3.62B |
| Sep/02 | $3.60B |
| Dec/02 | $3.99B |
| Mar/03 | $4.35B |
| Jun/03 | $4.42B |
| Sep/03 | $5.04B |
| Dec/03 | $5.46B |
| Mar/04 | $6.62B |
| Jun/04 | $6.84B |
| Sep/04 | $7.25B |
| Dec/04 | $7.47B |
| Mar/05 | $5.98B |
| Jun/05 | $3.04B |
| Sep/05 | $3.78B |
| Dec/05 | $5.80B |
| Mar/06 | $5.28B |
| Jun/06 | $5.36B |
| Sep/06 | $5.50B |
| Dec/06 | $4.01B |
| Mar/07 | $4.01B |
| Jun/07 | $4.65B |
| Sep/07 | $3.58B |
| Dec/07 | $2.23B |
| Mar/08 | $2.64B |
| Jun/08 | $4.40B |
| Sep/08 | $7.43B |
| Dec/08 | $8.27B |
| Mar/09 | $8.92B |
| Jun/09 | $8.12B |
| Sep/09 | $6.67B |
| Dec/09 | $8.51B |
Perspectives on Strategic M&A in Pharma by Pfizer Inc. Capital IQ Monthly Market Observations 03/10. $PFE,$MRK,$BMY,$LLY,$GSK,$JNJ,$NVS
HometownStocks about 17 hours ago.
Pharma trend: looking at complementary or diversified businesses. keynote by Kristin Peck. $PFE,$MRK,$BMY,$LLY,$GSK,$JNJ,$NVS
HometownStocks about 17 hours ago.
Pharma trend: Huge growth in emerging markets like China. keynote by Kristin Peck. $PFE,$MRK,$BMY,$LLY,$GSK,$JNJ,$NVS
HometownStocks about 18 hours ago.
Pharma trend:Pfizer/Wyeth,Merck/Schering,Roche/Genentech. cost synergy. diversifying revenue. keynote by Kristin Peck. $PFE,$MRK,$BMY,$LLY
HometownStocks about 18 hours ago.
Pharma trend: Revenue declines. Return on R&D declines. Industry consolidation. keynote by Kristin Peck. $PFE,$MRK,$BMY,$LLY,$GSK,$JNJ,$NVS
HometownStocks about 18 hours ago.
Pharma trend: Generic’s are the winners when things go off the patent. keynote by Kristin Peck. $PFE,$MRK,$BMY,$LLY,$GSK,$JNJ,$NVS
HometownStocks about 18 hours ago.
Pharma trend: loss of exclusivity, $314B in products patent expire in next 5 yrs. keynote by Kristin Peck.$PFE,$MRK,$BMY,$LLY,$GSK,$JNJ,$NVS
HometownStocks about 18 hours ago.
A Black-Box Warning for Plavix. Confusion May Follow (at The Wall Street Journal Online)
Mar 12 05:42 PM EST.
RT @mhuckman: While in the air,bloodthinner Plavix from Bristol&Sanofi $BMY $SNY got new boxed warning. FDA doesn't want us 2 call it 'black box' anymore.
blehr11 about 2 days ago.
RT @mhuckman: While in the air,bloodthinner Plavix from Bristol&Sanofi $BMY $SNY got new boxed warning. FDA doesn't want us 2 call it 'black box' anymore.
IJALM about 2 days ago.
While in the air,bloodthinner Plavix from Bristol&Sanofi $BMY $SNY got new boxed warning. FDA doesn't want us 2 call it 'black box' anymore.
mhuckman about 2 days ago.
Mar 12 01:08 PM EST.
Interesting BioSante GVAX data in leukemia targets minimal residual disease post imatinib therapy http://bit.ly/96tBLZ $BPAX $NVS $BMY
MaverickNY about 3 days ago.
$BMY (Bristol-Myers Squibb) $25.89 crossed its 1st Pivot Point Resistance #emppv #stocks http://empirasign.com/s/7y8
empirasign_eq about 3 days ago.
RT @mhuckman: Small co, small study fyi RT @MaverickNY: My take on the BioSante GVAX data in leukemia: http://bit.ly/96tBLZ $BPAX $NVS $BMY
Newbietrader1 about 3 days ago.
Small co, small study fyi RT @MaverickNY: My take on the BioSante GVAX data in leukemia: http://bit.ly/96tBLZ $BPAX $NVS $BMY
mhuckman about 3 days ago.
My take on the BioSante GVAX data in leukemia: http://bit.ly/96tBLZ $GPAX $NVS $BMY
MaverickNY about 3 days ago.
$BMY (Bristol-Myers Squibb) $25.62 crossed its 3rd Pivot Point Resistance #emppv #stocks http://empirasign.com/s/7e8
empirasign_eq about 4 days ago.
Biotechs Jump on Facet, Intermune Deal - Stocks To Watch Today - Barrons.com $ITMN $ABT $FACT $OSIP $JNJ $BMY $BSX $XBI http://bit.ly/aJDahM
barronsstocks about 4 days ago.
RT @MaverickNY: The Abbott-Facet Biotech deal: Let the dance begin http://bit.ly/bJF2eH $ABT $FACT $BMY $BIIB
WriterChik about 4 days ago.
Abbot Bids 66% Premium for Facet’s Oncology Drugs - Stocks To Watch Today - Barrons.com $ABT $FACT $JNJ $PFE $BSX $BMY http://bit.ly/cEfsR7
barronsstocks about 4 days ago.
RT @mhuckman: 1 more thing on Bristol $BMY CEO $1.5m pay cut last yr. Still made $18.2m, but said @ analyst mtg last wk he'll soon "b on fixed income."
mccannpj about 4 days ago.
1 more thing on Bristol $BMY CEO $1.5m pay cut last yr. Still made $18.2m, but said @ analyst mtg last wk he'll soon "b on fixed income."
mhuckman about 4 days ago.
RT @odomlewis: RT @mhuckman: How's this 4 a change? Bristol $BMY says CEO Cornelius took $1.5m pay cut last yr. Still made $18.2m[obscene]
MeredithGould about 4 days ago.
RT @mhuckman: How's this 4 a change? Bristol $BMY says CEO Cornelius took $1.5m pay cut last yr. Still made $18.2m, tho.
odomlewis about 4 days ago.
The Abbott-Facet Biotech deal: Let the dance begin http://bit.ly/bJF2eH $ABT $FACT $BMY $BIIB
MaverickNY about 4 days ago.
Looking forward to participating in SXSWi panel "Data Is Money" with @apatzer, @womanwportfolio, Jesper Anderson, Allison Brady #datamoney
about 17 hours ago. | Follow Us
